Remember only 33% on average will have been taking the 50 mg per day high dose. and 33% will have been taking a placebo during the Phase 2b/3 trial.
The answer to your question is that it depends on which cohort responds best and the strength of the response.
In the OLE (open label extension) study virtually all of the 476 participants will be taking 50 mg per day.
Primary Outcome Measures : ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition) [ Time Frame: 48 weeks ] Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog)
ADCS-ADL (Activities of Daily Living) [ Time Frame: 48 weeks ] Reduction in decline of the ability to perform daily activities assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Activities of Daily Living Scale (ADCS-ADL)
Secondary Outcome Measures : CDR-SB (Clinical Dementia Rating Scale Sum of Boxes) [ Time Frame: 48 weeks ] Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared with placebo using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 48 weeks ] Assess the safety and tolerability of ANAVEX2-73 compared to placebo
Market Data 
Markets 
